Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bipartisan Senate Finance Framework Takes ‘Measured’ Aim At PBMs

Executive Summary

Framework from Sens. Wyden and Crapo, looks like it would change, but not eliminate, the rebate system and gets an initial thumbs up from both the brand and generic drug lobbies.

You may also be interested in...

PBM Rebates Drive List-To-Net Price Gap For Insulins, Study Shows; More Fodder For Reforms?

Mandatory government discounts had a much smaller impact on net prices than voluntary rebates in commercial and Medicare Part D plans, researchers determine. The cap on Medicaid rebates, which will be eliminated in 2024, may have contributed to at least some of the disparity.

PBM Compensation 'Delinked' From List Price, Utilization In Medicare Part D Under Senate Bill

Legislation focuses on key aspect of Senate Finance Committee framework for reforming pharmacy benefit managers, reflecting concerns that current compensation practices reward PBMs for higher list prices and increase costs for patients. It does not take direct aim at rebates.

Senate Committee Passes Moderate PBM Reform, But Has Its Eyes On Stronger Policies

Delinking pharmacy benefits managers’ compensation from the prices of drugs received bipartisan rhetorical support at a HELP markup, but the panel only cleared less drastic PBM reforms along with generic and orphan-drug focused policies. Approved amendments tackled step therapy, pharma transparency and PBM gag clauses, among other topics.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts